Skip to main content

Table 1 Baseline patient demographics and MMSE scores (ITT set)

From: Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

  MOD-SEV subgroupa MOD subgroupb
Characteristic Memantine added to donepezil
( n = 264)
Placebo added to donepezil
( n = 246)
Memantine added to donepezil
( n = 186)
Placebo added to donepezil
( n = 181)
Female 155 (58.7) 151 (61.4) 114 (61.3) 110 (60.8)
Age, mean (SD) years 75.1 (8.5) 75.8 (8.5) 75.9 (8.4) 76.4 (8.2)
Caucasian 236 (89.4) 230 (93.5) 166 (89.2) 171 (94.5)
Black 10 (3.8) 6 (2.4) 5 (2.7) 4 (2.2)
Asian 3 (1.1) 1 (0.4) 3 (1.6) 1 (0.6)
Other 15 (5.7) 9 (3.7) 12 (6.5) 5 (2.8)
MMSE score, mean (SD) 11.9 (3.9) 11.7 (3.7) 13.9 (2.5) 13.4 (2.6)
  1. Data are number (%) unless otherwise specified. aModerate to severe Alzheimer's disease (AD) (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day). bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). MMSE, Mini-Mental State Examination; ITT, intention-to-treat.